2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 1 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 376 | - | - | ||
| 6 779 | - | - | ||
| 3 221 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenHow deep into the ASSURE study do you think it goes before a partner approaches Immunovia and says they want in before the values become more expensive with a Medicare approval in hand in the years ahead of us? The application to Medicare was supposed to happen this summer according to management. Asked AI a bit and it thinks that: "The "Smoking Gun" from the Board If there was any doubt that the company is angling for a major corporate transaction to break out of these doldrums, the Board of Directors just made it official at the Annual General Meeting on May 13. They officially resolved to implement a new option incentive program for management and board members that is tied directly to "exit events." The company explicitly defined these events as: The out-licensing of PancreaSure. Significant ownership changes (an acquisition). When a board creates equity incentives specifically paying out on an "exit event," it means they aren't trying to build a slow, multi-year organic sales business. They are dressed up and actively looking for a partner to dance with." (Gemini AI)- ·3 t sittenNow we are probably getting closer and closer to New York approval, aren't we? In February, Jeff Borcherding was probably very optimistic. And what did the nuance look like in the webcast in May? What boost will this give us?
- ·1 päivä sitten · MuokattuWe were at 20 öre today, May 19. Think it's a quite positive thing to see. Of course not where we have been before recently at 24-25 öre, but still a nice recovery, however long it may last then. Maybe this will be a decent week?
- ·13.5. · MuokattuMay 13. Over an hour of trading. Only 100 thousand shares traded. That is less than 20 thousand SEK. This is an all-time low trading volume for this stock.. The Swedish stock exchange closes at 1 PM today. Turnover characterized by downward manipulation. With large volumes for sale, and a gradual lowering of the price level. The mentioned pension fund that Immunovia's management so proudly highlighted probably has fixed trading times and is probably not active here now? (Avanza apparently). "Boring days right now"
- ·12.5. · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenHow deep into the ASSURE study do you think it goes before a partner approaches Immunovia and says they want in before the values become more expensive with a Medicare approval in hand in the years ahead of us? The application to Medicare was supposed to happen this summer according to management. Asked AI a bit and it thinks that: "The "Smoking Gun" from the Board If there was any doubt that the company is angling for a major corporate transaction to break out of these doldrums, the Board of Directors just made it official at the Annual General Meeting on May 13. They officially resolved to implement a new option incentive program for management and board members that is tied directly to "exit events." The company explicitly defined these events as: The out-licensing of PancreaSure. Significant ownership changes (an acquisition). When a board creates equity incentives specifically paying out on an "exit event," it means they aren't trying to build a slow, multi-year organic sales business. They are dressed up and actively looking for a partner to dance with." (Gemini AI)
- ·3 t sittenNow we are probably getting closer and closer to New York approval, aren't we? In February, Jeff Borcherding was probably very optimistic. And what did the nuance look like in the webcast in May? What boost will this give us?
- ·1 päivä sitten · MuokattuWe were at 20 öre today, May 19. Think it's a quite positive thing to see. Of course not where we have been before recently at 24-25 öre, but still a nice recovery, however long it may last then. Maybe this will be a decent week?
- ·13.5. · MuokattuMay 13. Over an hour of trading. Only 100 thousand shares traded. That is less than 20 thousand SEK. This is an all-time low trading volume for this stock.. The Swedish stock exchange closes at 1 PM today. Turnover characterized by downward manipulation. With large volumes for sale, and a gradual lowering of the price level. The mentioned pension fund that Immunovia's management so proudly highlighted probably has fixed trading times and is probably not active here now? (Avanza apparently). "Boring days right now"
- ·12.5. · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 376 | - | - | ||
| 6 779 | - | - | ||
| 3 221 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenHow deep into the ASSURE study do you think it goes before a partner approaches Immunovia and says they want in before the values become more expensive with a Medicare approval in hand in the years ahead of us? The application to Medicare was supposed to happen this summer according to management. Asked AI a bit and it thinks that: "The "Smoking Gun" from the Board If there was any doubt that the company is angling for a major corporate transaction to break out of these doldrums, the Board of Directors just made it official at the Annual General Meeting on May 13. They officially resolved to implement a new option incentive program for management and board members that is tied directly to "exit events." The company explicitly defined these events as: The out-licensing of PancreaSure. Significant ownership changes (an acquisition). When a board creates equity incentives specifically paying out on an "exit event," it means they aren't trying to build a slow, multi-year organic sales business. They are dressed up and actively looking for a partner to dance with." (Gemini AI)
- ·3 t sittenNow we are probably getting closer and closer to New York approval, aren't we? In February, Jeff Borcherding was probably very optimistic. And what did the nuance look like in the webcast in May? What boost will this give us?
- ·1 päivä sitten · MuokattuWe were at 20 öre today, May 19. Think it's a quite positive thing to see. Of course not where we have been before recently at 24-25 öre, but still a nice recovery, however long it may last then. Maybe this will be a decent week?
- ·13.5. · MuokattuMay 13. Over an hour of trading. Only 100 thousand shares traded. That is less than 20 thousand SEK. This is an all-time low trading volume for this stock.. The Swedish stock exchange closes at 1 PM today. Turnover characterized by downward manipulation. With large volumes for sale, and a gradual lowering of the price level. The mentioned pension fund that Immunovia's management so proudly highlighted probably has fixed trading times and is probably not active here now? (Avanza apparently). "Boring days right now"
- ·12.5. · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 376 | - | - | ||
| 6 779 | - | - | ||
| 3 221 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 803 568 | 803 568 | 0 | 0 |